FDA's Peter Marks to Congress: Youngest kids vaccine won't need to hit 50% efficacy mark

Zachary Brennan

Senior Editor

The FDA’s top vaccine leader told a congressional committee on Friday afternoon that although the adult vaccines had to meet a 50% threshold for efficacy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA's Peter Marks to Congress: Youngest kids vaccine won't need to hit 50% efficacy mark

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Biotech seed rounds sink to lowest level in years as industry slump drags on

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

FDA's Pe­ter Marks to Con­gress: Youngest kids vac­cine won't need to hit 50% ef­fi­ca­cy mark

Senior Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

FDA's Peter Marks to Congress: Youngest kids vaccine won't need to hit 50% efficacy mark